JWH 307 is discontinued (DEA controlled substance). It is a (1-naphthoyl)pyrrole cannabimimetic that potently activates both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors . Its physiological, neurological, and toxicological properties have not been evaluated. References: Hutter M, Broecker S, Kneisel S, Franz F, Brandt SD, Auwarter V. Metabolism of Synthetic Cannabinoid Receptor Agonists Encountered in Clinical Casework: Major in vivo Phase I Metabolites of JWH-007, JWH-019, JWH-203, JWH-307, UR-144, XLR-11, AM-2201, MAM-2201 and AM-694 in Human Urine Using LC-MS/MS. Curr Pharm Biotechnol. 2018 May 9. doi: 10.2174/1389201019666180509163114. [Epub ahead of print] PubMed PMID: 29745330.

纯度：≥98%

CAS：914458-26-7